Chien-Hsing Chang - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Chien-Hsing Chang

Showing results (31-40 of 97) with videos related to

Pageof 10

Sort By:

Cancer Research|September 30, 2010

A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cellsEdmund A Rossi, Diane L Rossi, Rhona Stein, et al.

Urolithiasis|December 15, 2015

Percutaneous nephrostomy versus ureteroscopic management of sepsis associated with ureteral stone impaction: a randomized controlled trialChung-Jing Wang, Chi-Sen Hsu, Hung-Wen Chen, et al.

Seminars in Nuclear Medicine|March 31, 2010

Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapyRobert M Sharkey, Edmund A Rossi, William J McBride, et al.

Molecular Cancer Therapeutics|May 22, 2016

Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric CancersChien-Hsing Chang, Yang Wang, Maria Zalath, et al.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 8, 2012

Pretargeting: taking an alternate route for localizing radionuclidesRobert M Sharkey, Chien-Hsing Chang, Edmund A Rossi, et al.

Molecular Cancer Therapeutics|July 24, 2014

Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-αEdmund A Rossi, Diane L Rossi, Thomas M Cardillo, et al.

Mabs|February 5, 2014

A new class of bispecific antibodies to redirect T cells for cancer immunotherapyDiane L Rossi, Edmund A Rossi, Thomas M Cardillo, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2007

Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargetingDavid M Goldenberg, Edmund A Rossi, Robert M Sharkey, et al.

Theranostics|June 28, 2012

Pretargeted molecular imaging and radioimmunotherapyDavid M Goldenberg, Chien-Hsing Chang, Edmund A Rossi, et al.

Blood|November 21, 2007

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of actionZhengxing Qu, David M Goldenberg, Thomas M Cardillo, et al.

Pageof 10

Search research articles

Showing results (31-40 of 97) with videos related to

Sort By:

Pageof 10

Cancer Research|September 30, 2010

A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cellsEdmund A Rossi, Diane L Rossi, Rhona Stein, et al.

Urolithiasis|December 15, 2015

Percutaneous nephrostomy versus ureteroscopic management of sepsis associated with ureteral stone impaction: a randomized controlled trialChung-Jing Wang, Chi-Sen Hsu, Hung-Wen Chen, et al.

Seminars in Nuclear Medicine|March 31, 2010

Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapyRobert M Sharkey, Edmund A Rossi, William J McBride, et al.

Molecular Cancer Therapeutics|May 22, 2016

Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric CancersChien-Hsing Chang, Yang Wang, Maria Zalath, et al.

Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 8, 2012

Pretargeting: taking an alternate route for localizing radionuclidesRobert M Sharkey, Chien-Hsing Chang, Edmund A Rossi, et al.

Molecular Cancer Therapeutics|July 24, 2014

Redirected T-cell killing of solid cancers targeted with an anti-CD3/Trop-2-bispecific antibody is enhanced in combination with interferon-αEdmund A Rossi, Diane L Rossi, Thomas M Cardillo, et al.

Mabs|February 5, 2014

A new class of bispecific antibodies to redirect T cells for cancer immunotherapyDiane L Rossi, Edmund A Rossi, Thomas M Cardillo, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2007

Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargetingDavid M Goldenberg, Edmund A Rossi, Robert M Sharkey, et al.

Theranostics|June 28, 2012

Pretargeted molecular imaging and radioimmunotherapyDavid M Goldenberg, Chien-Hsing Chang, Edmund A Rossi, et al.

Blood|November 21, 2007

Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of actionZhengxing Qu, David M Goldenberg, Thomas M Cardillo, et al.

Pageof 10